DUBLIN–(BUSINESS WIRE)–The “Cachexia – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
The “Cachexia – Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cachexia Emerging Drugs Chapters
This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cachexia Emerging Drugs
Macimorelin: AEterna Zentaris
Macimorelin (AEZS 130) is an orally active, small-molecule, being developed by AEterna Zentaris for the diagnosis of adult and pediatric growth hormone deficiency and for the treatment of cachexia associated with chronic diseases, such as AIDS and cancer. Macimorelin was approved by the FDA in December 2017 under the market name Macrilen for oral solution. Macimorelin stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus. The drug is currently being investigated in Phase II clinical to treat patients with Cancer Cachexia.
PF – 06946860: Pfizer
PF – 06946860 is a Growth Factor Blocker being investigated in Phase I stage of development. A 6 week double blind study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite has been initiated to find out how participants with advanced cancer and anorexia feel after receiving repeated doses injected under the skin.
Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cachexia
There are approx. 15+ key companies which are developing the therapies for Cachexia. The companies which have their Cachexia drug candidates in the mid to advanced stage, i.e. Phase II include, AEterna Zentaris.
Phases
The publisher’s report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III )
- Mid-Stage products (Phase II)
- Early-stage products ( Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Oral
Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Peptide
- Antibiotics
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cachexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cachexia.
Cachexia Report Insights
- Cachexia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cachexia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- GlaxoSmithKline
- AEterna Zentaris
- AVEO Pharmaceuticals, Inc.
- NGM Biopharmaceuticals
- Pfizer
- Endevica Bio
- Aphios coporation
- Actimed therapeutics
- TMS Co., Ltd.
- CatalYm GmbH
- Green Cross Wellbeing
- ImmunoForge
- Faraday Pharmaceuticals
- Immuneering
Key Products
- GSK2881078
- Macimorelin
- AV-380
- NGM120
- PF-06946860
- TCMCB07
- APH-0802
- ACM-001
- TMS-008
- CTL-002
- GCWB 204
- ACM-002
- PF-1801
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/950e27
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900